Should Investors Consider Semler Scientific? A Deep Dive with Adu Subramanian
In this week\u2019s podcast, 7investing lead advisor Luke Hallard catches up with health tech expert investor Adu Subramanian to chat about Semler Scientific (NASDAQ: SMLR) -- an exciting $300M heath care technology business that\u2019s rapidly becoming the standard of care for diagnosing peripheral arterial disease (PAD).
\nPAD is a condition that affects nearly 20 million Americans, yet it\u2019s estimated that only 25% of cases are diagnosed, resulting in costly interventions, and impacting the quality of life for patients.The company received FDA approval for its innovative product, QuantaFlo, in 2015, and today revenues are growing via a unique distribution model of selling directly into insurance companies.
\nIn this fun and lively interview, Adu shares his investing thesis for Semler Scientific, breaking down the business model, the incentives for doctors, insurers and patients, and the key financials and investment risks.
\nAdu Subramanian can be found on Twitter @AduSubramanian, or you can read his full investment thesis at his substack, Medtech and Microcaps.
\nWelcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year.
\nStart your journey toward's financial independence: https://www.7investing.com/subscribe
\nStop by our website to level-up your investing education: https://www.7investing.com
\nJoin the 7investing Community Forum: https://discord.gg/6YvazDf9sw
\nFollow us:
\n\u25ba https://www.facebook.com/7investing
\n\n